(Q38070693)

28 August 2017

0 references

1 reference

title

Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma (English)

1 reference

28 August 2017

main subject

liver transplantation

1 reference

1 reference

1 reference

K V Menon

1

1 reference

28 August 2017

A R Hakeem

series ordinal

2

1 reference

28 August 2017

N D Heaton

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

20 December 2012

1 reference

Alimentary Pharmacology & Therapeutics

28 August 2017

published in

1 reference

28 August 2017

volume

37

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

411-419

1 reference

Epidemiology of hepatocellular carcinoma in Hispanics in the United States

28 August 2017

cites work

1 reference

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance

21 January 2018

1 reference

21 January 2018

Hepatocellular carcinoma

1 reference

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging

21 January 2018

1 reference

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

21 January 2018

1 reference

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 January 2018

1 reference

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence

21 January 2018

1 reference

Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth

21 January 2018

1 reference

The role of mTOR inhibitors in the management of posttransplant malignancy

21 January 2018

1 reference

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

21 January 2018

1 reference

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

Systematic reviews of evaluations of prognostic variables

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

Evaluation of the quality of prognosis studies in systematic reviews

21 January 2018

1 reference

Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.

21 January 2018

1 reference

Indications and management of everolimus after liver transplantation.

21 January 2018

1 reference

Sirolimus in liver transplant recipients: a large single-center experience.

21 January 2018

1 reference

Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence

21 January 2018

1 reference

Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

Sirolimus therapy in liver transplant patients: an initial experience at a single center.

21 January 2018

1 reference

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.

21 January 2018

1 reference

Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria

21 January 2018

1 reference

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

21 January 2018

1 reference

Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase

21 January 2018

1 reference

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

21 January 2018

1 reference

Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth

21 January 2018

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

21 January 2018

1 reference

Causes of sirolimus discontinuation in 97 liver transplant recipients

21 January 2018

1 reference

Sirolimus for calcineurin inhibitors in organ transplantation: contra

21 January 2018

1 reference

Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma

21 January 2018

1 reference

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

21 January 2018

1 reference

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12185

1 reference

28 August 2017

1 reference